Last updated on February 2018

Evaluation of the Long Term Safety Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ) in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1 2 or 3.


Brief description of study

The purpose of the study is to evaluate how safe, how effective and how well tolerated, the study drug Olokizumab is, in the long-term, in patients with Rheumatoid Arthritis (RA) who have previously taken part in and completed 24 weeks of blinded treatment in one of the core studies - CREDO 1, 2 or 3.

Detailed Study Description

The goal of this Phase III study is to evaluate the long-term safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who previously completed 24 weeks of double-blind treatment with OKZ in the core studies. OKZ is expected to reduce the disease activity and induce an improvement in physical function. The study is expected to provide long-term safety information in a large group of subjects treated with OKZ for up to 106 weeks.

Clinical Study Identifier: NCT03120949

Contact Investigators or Research Sites near you

Start Over

Zuzana Urbanova

Revmatologicka ambulance
Praha 4 Nusle, Czechia
  Connect »

Zuzana Stejfova

Nuselska poliklinika
Praha 4, Czechia
1.16miles
  Connect »

Vlasta Gollerova

CLINTRIAL s.r.o.
Praha 10, Czechia
2.44miles
  Connect »

Jan Rosa

Affidea Praha s.r.o.
Praha, Czechia
3.56miles
  Connect »

Rudolf Horvath

Fakultni nemocnice v Motole
Praha 5, Czechia
4.81miles
  Connect »